Aβ oligomer induced cognitive impairment and evaluation of ACU193‐MNS‐based MRI in rabbit

Abstract Introduction Amyloid‐beta oligomers (AβOs) accumulate in Alzheimer's disease and may instigate neuronal pathology and cognitive impairment. We examined the ability of a new probe for molecular magnetic resonance imaging (MRI) to detect AβOs in vivo, and we tested the behavioral impact of AβOs injected in rabbits, a species with an amino acid sequence that is nearly identical to the human sequence. Methods Intracerebroventricular (ICV) injection with stabilized AβOs was performed. Rabbits were probed for AβO accumulation using ACUMNS (an AβO‐selective antibody [ACU193] coupled to magnetic nanostructures). Immunohistochemistry was used to verify AβO presence. Cognitive impairment was evaluated using object location and object recognition memory tests and trace eyeblink conditioning. Results AβOs in the entorhinal cortex of ICV‐injected animals were detected by MRI and confirmed by immunohistochemistry. Injections of AβOs also impaired hippocampal‐dependent, but not hippocampal‐independent, tasks and the area fraction of bound ACUMNs correlated with the behavioral impairment. Discussion Accumulation of AβOs can be visualized in vivo by MRI of ACUMNS and the cognitive impairment induced by the AβOs can be followed longitudinally with the novel location memory test.

[1]  Luis F. Schachner,et al.  A novel crosslinking protocol stabilizes amyloid β oligomers capable of inducing Alzheimer's‐associated pathologies , 2019, Journal of neurochemistry.

[2]  J. Ainge,et al.  Fan Cells in Layer 2 of the Lateral Entorhinal Cortex Are Critical for Episodic-like Memory , 2019, Current Biology.

[3]  J. Disterhoft,et al.  Differential responsivity of neurons in perirhinal cortex, lateral entorhinal cortex, and dentate gyrus during time‐bridging learning , 2018, Hippocampus.

[4]  M. Schöll,et al.  In vivo Detection of Alzheimer’s Disease , 2018, The Yale journal of biology and medicine.

[5]  E. Bayram,et al.  Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer's disease , 2018, Alzheimer's & dementia.

[6]  W. Klein,et al.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade , 2018, Journal of Alzheimer's disease : JAD.

[7]  D. Munoz,et al.  The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease , 2018, The Journal of pathology.

[8]  Craig Weiss,et al.  The rabbit as a behavioral model system for magnetic resonance imaging , 2017, Journal of Neuroscience Methods.

[9]  Lei Wang,et al.  Intrinsic connectivity of neural networks in the awake rabbit , 2016, NeuroImage.

[10]  V. Dravid,et al.  Engineered Theranostic Magnetic Nanostructures: Role of Composition and Surface Coating on Magnetic Resonance Imaging Contrast and Thermal Activation. , 2016, ACS applied materials & interfaces.

[11]  C. Luan,et al.  Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer’s-Associated Aβ Oligomers , 2015, PloS one.

[12]  Vinayak P. Dravid,et al.  Towards Non-Invasive Diagnostic Imaging of Early-Stage Alzheimer’s Disease , 2014, Nature nanotechnology.

[13]  Annie Vogel-Ciernia,et al.  Examining Object Location and Object Recognition Memory in Mice , 2014, Current protocols in neuroscience.

[14]  A. Lang,et al.  Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau45-230 transgenic mice , 2014, Neuroscience.

[15]  J. Renger,et al.  A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid , 2014, The Journal of Neuroscience.

[16]  G. Krafft,et al.  ACU-193: A candidate therapeutic antibody that selectively targets soluble beta-amyloid oligomers , 2013, Alzheimer's & Dementia.

[17]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[18]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[19]  W. Klein,et al.  Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease , 2012, Neurobiology of Aging.

[20]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[21]  Heike Wulff,et al.  Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity* , 2010, The Journal of Biological Chemistry.

[22]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[23]  Rie Teraoka,et al.  A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.

[24]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[25]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[26]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[27]  W. K. Cullen,et al.  Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization , 2008, The Journal of Neuroscience.

[28]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[29]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[30]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[31]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[32]  Philippe Robert,et al.  Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.

[33]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[34]  N. Fullwood,et al.  Hydrogen Peroxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia* , 2005, Journal of Biological Chemistry.

[35]  D. Sparks,et al.  Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  I. Sponne,et al.  Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid-β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation* , 2003, The Journal of Biological Chemistry.

[37]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Finch,et al.  Reversible Inactivation of Superoxide‐Sensitive Aconitase in Aβ1‐42‐Treated Neuronal Cell Lines , 2000, Journal of neurochemistry.

[39]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Chromy,et al.  Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release , 1998, Brain Research.

[41]  R. Petersen,et al.  Aging, Memory, and Mild Cognitive Impairment , 1997, International Psychogeriatrics.

[42]  Richard F. Thompson,et al.  Hippocampectomy impairs the memory of recently, but not remotely, acquired trace eyeblink conditioned responses. , 1995, Behavioral neuroscience.

[43]  P. Kotikalapudi,et al.  Sequence and nethylation in the βA4 region of the rabbit anyloid precursor protein gene , 1992 .

[44]  Richard F. Thompson,et al.  Hippocampus and trace conditioning of the rabbit's classically conditioned nictitating membrane response. , 1986, Behavioral neuroscience.

[45]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[46]  O. Ghribi.  Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. , 2008, Journal of Alzheimer's disease : JAD.

[47]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[48]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[49]  R. Stelzmann,et al.  An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde” , 1995, Clinical anatomy.

[50]  J. Disterhoft,et al.  Hippocampectomy disrupts trace eye-blink conditioning in rabbits. , 1990, Behavioral neuroscience.

[51]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.